APLS Price Prediction Next Week
Based on the provided data and context, I'll analyze APLS's price movement and provide a prediction for next week.
Technical Analysis
- Current price: $25.20 (as of market close on Feb 28, 2025)
- Recent price action shows significant volatility:
- Open: $26.00
- High: $26.05
- Low: $24.33
- Close: $25.15
- Volume: 2,958,362
- The stock experienced a notable decline of -3.27% during regular market hours
- Minor recovery in after-hours trading (+0.20%)
Market Environment & News Impact
- The broader market is showing signs of weakness, with major indices experiencing declines due to:
- Implementation of new tariffs announced by President Trump
- Rising jobless claims indicating potential economic slowdown
- General market uncertainty around trade policies
Price Prediction for Next Week
Based on technical indicators and current market conditions:
Target Levels:
- Resistance: $26.05 (recent high)
- Support: $24.33 (recent low)
Scenarios:
Bearish Case (60% probability):
- Price likely to test support at $24.33
- If broken, next support around $23.50
- Target: $23.50-24.00
Bullish Case (30% probability):
- Bounce from current levels
- Resistance at $26.05 needs to be cleared
- Target: $26.50-27.00
Neutral Case (10% probability):
- Consolidation between $24.50-$25.50
Trading Recommendation SELL with the following parameters:
- Entry: Current market price ($25.20)
- Stop Loss: $26.25 (above recent high)
- First Target: $24.30
- Second Target: $23.50
Rationale:
- Negative market sentiment due to trade tensions
- Technical weakness shown in recent price action
- High probability of continued downward pressure
APLS Similar Chart Price Prediction
The price of APLS is predicted to go up 18.95%, based on the high correlation periods with JELD. The similarity of these two price pattern on the periods is 90.25%.
APLS
JELD
Up: 18.95%Similarity: 90.25%
APLS Revenue Forecast
APLS EPS Forecast
APLS FAQs
What is bull’s view on APLS?
What is bear's view on APLS?
What is APLS revenue forecast for next quarter？
APLS Analyst's Forecast
Salveen Richter
Goldman Sachs
Strong Buy → Hold
2024-12-17
Price Target
$36
Upside
+5.17%
Goldman Sachs downgraded Apellis to Neutral from Buy with a $36 price target. The firm's key opinion leader discussions indicate the actual number of geographic atrophy patients that physicians would treat with Apellis' lead drug, Syfovre or the competitor, Astellas' Izervay is smaller than anticipated. Goldman sees a slow progressing launch on the forward, saying a lack of clear functional benefit data limits broader uptake. Together these point to a more conservative commercial outlook for Apellis, the analyst tells investors in a research note.
Judah Frommer
Morgan Stanley
Hold
2024-11-21
Price Target
$31
Upside
+13.43%
Colleen Kusy
Baird
Buy
2024-11-07
Price Target
$92 → $55
Upside
+89.52%
